Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sangxingzhike granules is a Traditional Chinese Medicine (TCM) hospital preparation developed by the Xinjiang Uygur Autonomous Region Hospital of Traditional Chinese Medicine. It is primarily indicated for the treatment of post-infection cough (PIC), particularly cases characterized by the TCM syndrome of wind-dryness attacking the lung. The formulation is derived from the classic Sangxing Tang and typically includes botanical ingredients such as Folium Mori (Mulberry Leaf) and Semen Armeniacae Amarum (Bitter Apricot Seed). It functions by clearing heat, moistening the lungs, and suppressing cough. Clinical studies conducted by the developer have evaluated its efficacy in reducing cough frequency and severity compared to standard treatments like montelukast or methoxyphenamine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sangxingzhike granules.